XUANZHUBIO-B (02575)

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

XUANZHUBIO-B (02575)

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates includes Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and and XZP-3621, a first-line treatment for patients with anaplasti

CS Hotline: +852 3018 4526

Trading days: 24 hours | Non-trading days: 9:00-18:00

Headquarters

Sheung Wan

Address: Room 2405-06, 24/F, 308 Central Des Voeux, Sheung Wan, Hong Kong

North District

Address: 1718-1721, Level 17 Landmark North, 39 Lung Sum Avenue, Sheung Shui, New Territories, Hong Kong

Email: cs@usmart.hk

WhatsApp: +852 5989 2641

uSMART Branches(Causeway Bay coming soon)

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907) holding Type 1 Licence for Dealing in Securities, Type 4 Licence for Advising on Securities, Type 6 Licence for Advising on Corporate Finance, and Type 9 Licence for Asset Management.

Market News

XUANZHUBIO-B (02575)

Services

About Us

Agreement Statement